{"id": "article-57164_0", "title": "Chlorthalidone -- Continuing Education Activity", "content": "Chlorthalidone is a thiazide-like diuretic used to treat hypertension. This activity\u00a0discusses\u00a0chlorthalidone's\u00a0indications and contraindications\u00a0when managing hypertension, edema, and calcium nephrolithiasis.\u00a0Additionally, its mechanism of action, adverse event profile, pharmacokinetics, monitoring, and clinical toxicology are discussed. By exploring these aspects, healthcare professionals understand chlorthalidone's pharmacology, empowering them to tailor treatment plans to individual patient needs. By emphasizing the crucial role of the interprofessional healthcare team, this initiative equips participants with essential knowledge and tools to optimize patient care during chlorthalidone administration, thereby improving patient outcomes through evidence-based medicine.", "contents": "Chlorthalidone -- Continuing Education Activity. Chlorthalidone is a thiazide-like diuretic used to treat hypertension. This activity\u00a0discusses\u00a0chlorthalidone's\u00a0indications and contraindications\u00a0when managing hypertension, edema, and calcium nephrolithiasis.\u00a0Additionally, its mechanism of action, adverse event profile, pharmacokinetics, monitoring, and clinical toxicology are discussed. By exploring these aspects, healthcare professionals understand chlorthalidone's pharmacology, empowering them to tailor treatment plans to individual patient needs. By emphasizing the crucial role of the interprofessional healthcare team, this initiative equips participants with essential knowledge and tools to optimize patient care during chlorthalidone administration, thereby improving patient outcomes through evidence-based medicine."}
{"id": "article-57164_1", "title": "Chlorthalidone -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of chlorthalidone. Assess the potential adverse effects of chlorthalidone. Determine the\u00a0appropriate monitoring for patients on therapy with chlorthalidone. Implement\u00a0interprofessional team strategies for improving care coordination and communication to advance proper chlorthalidone administration and verify medication allergies. Access free multiple choice questions on this topic.", "contents": "Chlorthalidone -- Continuing Education Activity. Objectives: Identify the mechanism of action of chlorthalidone. Assess the potential adverse effects of chlorthalidone. Determine the\u00a0appropriate monitoring for patients on therapy with chlorthalidone. Implement\u00a0interprofessional team strategies for improving care coordination and communication to advance proper chlorthalidone administration and verify medication allergies. Access free multiple choice questions on this topic."}
{"id": "article-57164_2", "title": "Chlorthalidone -- Indications", "content": "Chlorthalidone is a thiazide-like sulfonamide-derived diuretic that has been FDA-approved since 1960 to manage hypertension. [1]", "contents": "Chlorthalidone -- Indications. Chlorthalidone is a thiazide-like sulfonamide-derived diuretic that has been FDA-approved since 1960 to manage hypertension. [1]"}
{"id": "article-57164_3", "title": "Chlorthalidone -- Indications -- FDA-Approved Indications", "content": "Chlorthalidone is a first-line agent for the treatment of hypertension. [2] This medication is utilized both\u00a0as an isolated agent and in combination with other antihypertensive drugs, including \u03b2-blockers or clonidine.\u00a0Chlorthalidone is\u00a0also used to treat edema. [3] The utility\u00a0for edema comes in multiple settings, including congestive heart failure, hepatic cirrhosis, corticosteroid therapy, as well as renal dysfunction, including chronic renal failure, nephrotic syndrome, and acute glomerular nephritis. [3]", "contents": "Chlorthalidone -- Indications -- FDA-Approved Indications. Chlorthalidone is a first-line agent for the treatment of hypertension. [2] This medication is utilized both\u00a0as an isolated agent and in combination with other antihypertensive drugs, including \u03b2-blockers or clonidine.\u00a0Chlorthalidone is\u00a0also used to treat edema. [3] The utility\u00a0for edema comes in multiple settings, including congestive heart failure, hepatic cirrhosis, corticosteroid therapy, as well as renal dysfunction, including chronic renal failure, nephrotic syndrome, and acute glomerular nephritis. [3]"}
{"id": "article-57164_4", "title": "Chlorthalidone -- Indications -- FDA-Approved Indications", "content": "Chlorthalidone was\u00a0first used as an antihypertensive agent and effectively manages blood pressure by decreasing intravascular volume through promoted diuresis. Per the 2017 guideline for the prevention, detection, evaluation, and management of high blood pressure, chlorthalidone can be used as a first-line age in the setting of hypertension when there are no contraindications or contributory comorbidities. [4] However, patients with cerebrovascular disease, advanced chronic kidney disease, diabetes, and heart failure treatment would preferably receive therapy with angiotensin-converting enzyme-inhibiting medication (ACE-I). These guidelines suggest that dihydropyridine calcium channel blockers and thiazide-like diuretics are the preferred agents without comorbidities because of better cardiovascular outcomes, specifically the reduced risk of heart failure and cerebral vascular accident. [5]", "contents": "Chlorthalidone -- Indications -- FDA-Approved Indications. Chlorthalidone was\u00a0first used as an antihypertensive agent and effectively manages blood pressure by decreasing intravascular volume through promoted diuresis. Per the 2017 guideline for the prevention, detection, evaluation, and management of high blood pressure, chlorthalidone can be used as a first-line age in the setting of hypertension when there are no contraindications or contributory comorbidities. [4] However, patients with cerebrovascular disease, advanced chronic kidney disease, diabetes, and heart failure treatment would preferably receive therapy with angiotensin-converting enzyme-inhibiting medication (ACE-I). These guidelines suggest that dihydropyridine calcium channel blockers and thiazide-like diuretics are the preferred agents without comorbidities because of better cardiovascular outcomes, specifically the reduced risk of heart failure and cerebral vascular accident. [5]"}
{"id": "article-57164_5", "title": "Chlorthalidone -- Indications -- FDA-Approved Indications", "content": "The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack) trial compared other first-line antihypertensives such as calcium channel blockers and angiotensin-converting-enzyme-inhibitors (ACE-I) against chlorthalidone.\u00a0The trial concluded that thiazide-like diuretics should be considered in the first-line treatment in\u00a0patients with hypertension as chlorthalidone had less association with stroke than ACE-I and less association with heart failure compared to calcium channel blockers. The results of this study were attributed to the earlier and more significant decrease in blood pressure, specifically systolic, from chlorthalidone compared to lisinopril and amlodipine. [5]", "contents": "Chlorthalidone -- Indications -- FDA-Approved Indications. The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack) trial compared other first-line antihypertensives such as calcium channel blockers and angiotensin-converting-enzyme-inhibitors (ACE-I) against chlorthalidone.\u00a0The trial concluded that thiazide-like diuretics should be considered in the first-line treatment in\u00a0patients with hypertension as chlorthalidone had less association with stroke than ACE-I and less association with heart failure compared to calcium channel blockers. The results of this study were attributed to the earlier and more significant decrease in blood pressure, specifically systolic, from chlorthalidone compared to lisinopril and amlodipine. [5]"}
{"id": "article-57164_6", "title": "Chlorthalidone -- Indications -- Off-Label Uses", "content": "Chlorthalidone helps treat calcium nephrolithiasis, M\u00e9ni\u00e8re disease, and diabetes insipidus, although it does not have FDA approval for these indications. [6] [7] [8] [7] Chlorthalidone\u00a0treats these\u00a0conditions by antagonizing the sodium chloride co-transporter in the distal convoluted tubule (DCT) in the loop of Henle. [9] Per the American Urological Association (AUA) guidelines, thiazide diuretics or chlorthalidone are recommended in patients with\u00a0high or relatively high urine calcium levels and experiencing recurrent calcium stones. [10]", "contents": "Chlorthalidone -- Indications -- Off-Label Uses. Chlorthalidone helps treat calcium nephrolithiasis, M\u00e9ni\u00e8re disease, and diabetes insipidus, although it does not have FDA approval for these indications. [6] [7] [8] [7] Chlorthalidone\u00a0treats these\u00a0conditions by antagonizing the sodium chloride co-transporter in the distal convoluted tubule (DCT) in the loop of Henle. [9] Per the American Urological Association (AUA) guidelines, thiazide diuretics or chlorthalidone are recommended in patients with\u00a0high or relatively high urine calcium levels and experiencing recurrent calcium stones. [10]"}
{"id": "article-57164_7", "title": "Chlorthalidone -- Indications -- Thiazide-like Medication Versus Thiazide-type Diuretics", "content": "Thiazide-type medications, most commonly hydrochlorothiazide (HCTZ), have been around longer than thiazide-like antihypertensives and were previously utilized more substantially. However, multiple studies have shown a preference for thiazide-like medications over their original counterparts. A 2015 systematic review showed that\u00a0chlorthalidone alleviated hypertensive burden by about 5.1 mm Hg of systolic blood pressure than HCTZ, finding chlorthalidone more potent than HCTZ. [11]", "contents": "Chlorthalidone -- Indications -- Thiazide-like Medication Versus Thiazide-type Diuretics. Thiazide-type medications, most commonly hydrochlorothiazide (HCTZ), have been around longer than thiazide-like antihypertensives and were previously utilized more substantially. However, multiple studies have shown a preference for thiazide-like medications over their original counterparts. A 2015 systematic review showed that\u00a0chlorthalidone alleviated hypertensive burden by about 5.1 mm Hg of systolic blood pressure than HCTZ, finding chlorthalidone more potent than HCTZ. [11]"}
{"id": "article-57164_8", "title": "Chlorthalidone -- Indications -- Thiazide-like Medication Versus Thiazide-type Diuretics", "content": "In addition to potency, studies have demonstrated that chlorthalidone holds a longer duration of action than HCTZ, 24 hours with chlorthalidone versus 6\u00a0to 12 hours with HCTZ. This increased duration of action allows for increased flexibility in dosing. [11] A study has shown that as a result of this longer duration of action, chlorthalidone is 1.5\u00a0to 2.0 times more efficacious at lowering systolic blood pressure than HCTZ (comparative antihypertensive effects between hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.) [12]", "contents": "Chlorthalidone -- Indications -- Thiazide-like Medication Versus Thiazide-type Diuretics. In addition to potency, studies have demonstrated that chlorthalidone holds a longer duration of action than HCTZ, 24 hours with chlorthalidone versus 6\u00a0to 12 hours with HCTZ. This increased duration of action allows for increased flexibility in dosing. [11] A study has shown that as a result of this longer duration of action, chlorthalidone is 1.5\u00a0to 2.0 times more efficacious at lowering systolic blood pressure than HCTZ (comparative antihypertensive effects between hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.) [12]"}
{"id": "article-57164_9", "title": "Chlorthalidone -- Indications -- Cardiovascular Outcomes", "content": "When considering antihypertensive medications, the effect on cardiovascular outcomes is of the highest concern. The ALLHAT trial showed a decreased risk of heart failure exacerbation\u00a0and cerebral vascular accidents compared to amlodipine and lisinopril, respectively. [5] [13] Additionally, a 2012 meta-analysis of\u00a0over 100,000 patients concluded that chlorthalidone and thiazide-like diuretics lowered the risk of heart failure by 21% and cardiovascular events by 12%. In comparison, thiazide-type HCTZ did not show improved outcomes compared to placebo. [5]", "contents": "Chlorthalidone -- Indications -- Cardiovascular Outcomes. When considering antihypertensive medications, the effect on cardiovascular outcomes is of the highest concern. The ALLHAT trial showed a decreased risk of heart failure exacerbation\u00a0and cerebral vascular accidents compared to amlodipine and lisinopril, respectively. [5] [13] Additionally, a 2012 meta-analysis of\u00a0over 100,000 patients concluded that chlorthalidone and thiazide-like diuretics lowered the risk of heart failure by 21% and cardiovascular events by 12%. In comparison, thiazide-type HCTZ did not show improved outcomes compared to placebo. [5]"}
{"id": "article-57164_10", "title": "Chlorthalidone -- Mechanism of Action", "content": "Chlorthalidone\u00a0exerts its therapeutic action by antagonizing sodium-chloride symporter in the distal convoluted tubule of the nephron.\u00a0This drug is similar to a thiazide diuretic in its mechanism of action, although it has a mildly altered chemical structure. Both thiazide and thiazide-like diuretics contain a sulfonamide group that also works to inhibit carbonic anhydrase and its antagonistic action at the distal convoluted tubule. [11]", "contents": "Chlorthalidone -- Mechanism of Action. Chlorthalidone\u00a0exerts its therapeutic action by antagonizing sodium-chloride symporter in the distal convoluted tubule of the nephron.\u00a0This drug is similar to a thiazide diuretic in its mechanism of action, although it has a mildly altered chemical structure. Both thiazide and thiazide-like diuretics contain a sulfonamide group that also works to inhibit carbonic anhydrase and its antagonistic action at the distal convoluted tubule. [11]"}
{"id": "article-57164_11", "title": "Chlorthalidone -- Mechanism of Action", "content": "Chlorthalidone inhibits sodium reabsorption at the level of the distal convoluted tubule and thus chloride via inhibition of the Na-Cl\u00a0symporter. By removing sodium reabsorption at this location, the distal convoluted tubule of the nephron retains a higher sodium content. This lack of reabsorption alters the osmotic gradient and shifts fluid distribution from the outside of the tubule to the inside of the tubule. The increased osmotic load from its elevated sodium concentration leads to elevated intratubular volume, thus promoting its diuretic effect. The\u00a0increased elimination of sodium and extracellular fluid leads to a reduction in intravascular water and solute concentration.\u00a0Reduction of\u00a0the intravascular volume and osmotic gradient decreases hydrostatic pressure, ultimately leading to a clinically significant decrease in blood pressure.", "contents": "Chlorthalidone -- Mechanism of Action. Chlorthalidone inhibits sodium reabsorption at the level of the distal convoluted tubule and thus chloride via inhibition of the Na-Cl\u00a0symporter. By removing sodium reabsorption at this location, the distal convoluted tubule of the nephron retains a higher sodium content. This lack of reabsorption alters the osmotic gradient and shifts fluid distribution from the outside of the tubule to the inside of the tubule. The increased osmotic load from its elevated sodium concentration leads to elevated intratubular volume, thus promoting its diuretic effect. The\u00a0increased elimination of sodium and extracellular fluid leads to a reduction in intravascular water and solute concentration.\u00a0Reduction of\u00a0the intravascular volume and osmotic gradient decreases hydrostatic pressure, ultimately leading to a clinically significant decrease in blood pressure."}
{"id": "article-57164_12", "title": "Chlorthalidone -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Chlorthalidone typically begins to exert its therapeutic effects within 3 hours of administration, with peak plasma concentrations achieved 2 to 6 hours after the dose. Distribution: Chlorthalidone exhibits high protein binding, predominantly to albumin, owing to its affinity for erythrocyte carbonic anhydrase. Metabolism: Chlorthalidone undergoes partial hepatic metabolism.", "contents": "Chlorthalidone -- Mechanism of Action -- Pharmacokinetics. Absorption: Chlorthalidone typically begins to exert its therapeutic effects within 3 hours of administration, with peak plasma concentrations achieved 2 to 6 hours after the dose. Distribution: Chlorthalidone exhibits high protein binding, predominantly to albumin, owing to its affinity for erythrocyte carbonic anhydrase. Metabolism: Chlorthalidone undergoes partial hepatic metabolism."}
{"id": "article-57164_13", "title": "Chlorthalidone -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Renal excretion plays a pivotal role in eliminating chlorthalidone from the body, with the major portion excreted unchanged via the kidneys.\u00a0This drug's elimination half-life ranges from 45 to 60 hours, contributing to its sustained duration of action, which typically lasts between 48 to 72 hours. [14]", "contents": "Chlorthalidone -- Mechanism of Action -- Pharmacokinetics. Excretion: Renal excretion plays a pivotal role in eliminating chlorthalidone from the body, with the major portion excreted unchanged via the kidneys.\u00a0This drug's elimination half-life ranges from 45 to 60 hours, contributing to its sustained duration of action, which typically lasts between 48 to 72 hours. [14]"}
{"id": "article-57164_14", "title": "Chlorthalidone -- Administration -- Available Dosage Forms", "content": "Chlorthalidone\u00a0is available solely as an oral medication.\u00a0The fixed-dose combination of atenolol/chlorthalidone, azilsartan/chlorthalidone, and clonidine/chlorthalidone is also available. [15]", "contents": "Chlorthalidone -- Administration -- Available Dosage Forms. Chlorthalidone\u00a0is available solely as an oral medication.\u00a0The fixed-dose combination of atenolol/chlorthalidone, azilsartan/chlorthalidone, and clonidine/chlorthalidone is also available. [15]"}
{"id": "article-57164_15", "title": "Chlorthalidone -- Administration -- Available Strengths", "content": "Chlorthalidone is available in 15 mg, 25 mg, and 50 mg tablets.", "contents": "Chlorthalidone -- Administration -- Available Strengths. Chlorthalidone is available in 15 mg, 25 mg, and 50 mg tablets."}
{"id": "article-57164_16", "title": "Chlorthalidone -- Administration -- Adult Dosage", "content": "Dosing regimens vary depending on clinical indication. For the treatment of heart failure, guidelines recommend starting at 12.5 mg or 25 mg daily and titrating up to 100 mg daily as necessary. For generalized edema, dosing begins with 50\u00a0to 100 mg daily and can be titrated to a maximum of 200 mg daily. As outlined below, chlorthalidone can\u00a0also be utilized to manage calcium nephrolithiasis, which is generalized administered at 25 mg daily. Hypertension: starting\u00a0dose of 12.5 to 25 mg daily, maximum dose of 100 mg daily (ACC/AHA) [16] Heart failure: starting\u00a0dose of 12.5 mg or 25 mg daily, maximum dose of 100 mg daily (ACC/AHA/HFSA) [17] Generalized edema: starting\u00a0dose of 12.5 to 25 mg orally once to twice daily, maximum dose of 100 mg daily (ACC Expert Consensus) [18] Calcium nephrolithiasis (off-label): 25 mg daily", "contents": "Chlorthalidone -- Administration -- Adult Dosage. Dosing regimens vary depending on clinical indication. For the treatment of heart failure, guidelines recommend starting at 12.5 mg or 25 mg daily and titrating up to 100 mg daily as necessary. For generalized edema, dosing begins with 50\u00a0to 100 mg daily and can be titrated to a maximum of 200 mg daily. As outlined below, chlorthalidone can\u00a0also be utilized to manage calcium nephrolithiasis, which is generalized administered at 25 mg daily. Hypertension: starting\u00a0dose of 12.5 to 25 mg daily, maximum dose of 100 mg daily (ACC/AHA) [16] Heart failure: starting\u00a0dose of 12.5 mg or 25 mg daily, maximum dose of 100 mg daily (ACC/AHA/HFSA) [17] Generalized edema: starting\u00a0dose of 12.5 to 25 mg orally once to twice daily, maximum dose of 100 mg daily (ACC Expert Consensus) [18] Calcium nephrolithiasis (off-label): 25 mg daily"}
{"id": "article-57164_17", "title": "Chlorthalidone -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: No dosage adjustments for chlorthalidone are provided in the product\u00a0labeling; use caution.", "contents": "Chlorthalidone -- Administration -- Specific Patient Populations. Hepatic impairment: No dosage adjustments for chlorthalidone are provided in the product\u00a0labeling; use caution."}
{"id": "article-57164_18", "title": "Chlorthalidone -- Administration -- Specific Patient Populations", "content": "Renal impairment: According to the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines, thiazide diuretics lose efficacy in diuresis and lower blood pressure as the glomerular filtration rate (GFR) worsens. However, chlorthalidone remains effective at a GFR <30 mL/min/1.73 m\u00b2. [19] In a double-blind, randomized, placebo-controlled trial among patients with stage 4 chronic kidney disease (eGFR 15 to 30 mL/min/1.73 m\u00b2) and uncontrolled hypertension, chlorthalidone therapy significantly improved blood pressure control compared to placebo at 12 weeks. [20]", "contents": "Chlorthalidone -- Administration -- Specific Patient Populations. Renal impairment: According to the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines, thiazide diuretics lose efficacy in diuresis and lower blood pressure as the glomerular filtration rate (GFR) worsens. However, chlorthalidone remains effective at a GFR <30 mL/min/1.73 m\u00b2. [19] In a double-blind, randomized, placebo-controlled trial among patients with stage 4 chronic kidney disease (eGFR 15 to 30 mL/min/1.73 m\u00b2) and uncontrolled hypertension, chlorthalidone therapy significantly improved blood pressure control compared to placebo at 12 weeks. [20]"}
{"id": "article-57164_19", "title": "Chlorthalidone -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: There is insufficient research to check teratogenicity, but\u00a0chlorthalidone\u00a0should be used only during pregnancy if\u00a0absolutely necessary.\u00a0Observational studies suggest that chlorthalidone use in pregnancy does not significantly increase the risk of major congenital disabilities or miscarriage. However, thiazide diuretics, including chlorthalidone, have been associated with adverse fetal outcomes such as jaundice, thrombocytopenia, hypoglycemia, and electrolyte imbalances. Consequently, chlorthalidone is not the preferred first-line treatment for hypertension in pregnancy. While chlorthalidone/thiazides do not prevent or alter the course of pre-eclampsia, they should not be the primary therapy for hypertension during pregnancy.", "contents": "Chlorthalidone -- Administration -- Specific Patient Populations. Pregnancy considerations: There is insufficient research to check teratogenicity, but\u00a0chlorthalidone\u00a0should be used only during pregnancy if\u00a0absolutely necessary.\u00a0Observational studies suggest that chlorthalidone use in pregnancy does not significantly increase the risk of major congenital disabilities or miscarriage. However, thiazide diuretics, including chlorthalidone, have been associated with adverse fetal outcomes such as jaundice, thrombocytopenia, hypoglycemia, and electrolyte imbalances. Consequently, chlorthalidone is not the preferred first-line treatment for hypertension in pregnancy. While chlorthalidone/thiazides do not prevent or alter the course of pre-eclampsia, they should not be the primary therapy for hypertension during pregnancy."}
{"id": "article-57164_20", "title": "Chlorthalidone -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: The concentration of chlorthalidone in breast milk is relatively low; however, the drug's prolonged clearance kinetics can result in its accumulation in newborns, particularly in premature infants. Additionally, chlorthalidone's pharmacological properties may inhibit lactation. Therefore, an alternative medication may be considered to minimize potential risks associated with infant exposure to chlorthalidone via breast milk. [21]", "contents": "Chlorthalidone -- Administration -- Specific Patient Populations. Breastfeeding considerations: The concentration of chlorthalidone in breast milk is relatively low; however, the drug's prolonged clearance kinetics can result in its accumulation in newborns, particularly in premature infants. Additionally, chlorthalidone's pharmacological properties may inhibit lactation. Therefore, an alternative medication may be considered to minimize potential risks associated with infant exposure to chlorthalidone via breast milk. [21]"}
{"id": "article-57164_21", "title": "Chlorthalidone -- Administration -- Specific Patient Populations", "content": "Pediatric patients: The safety and efficacy of chlorthalidone in pediatric populations have not been conclusively established.\u00a0As per the American Academy of Pediatrics (AAP), the initial recommended dose of chlorthalidone is 0.3 mg/kg, with a maximum daily dose of 2 mg/kg (or 50 mg per day). [22]", "contents": "Chlorthalidone -- Administration -- Specific Patient Populations. Pediatric patients: The safety and efficacy of chlorthalidone in pediatric populations have not been conclusively established.\u00a0As per the American Academy of Pediatrics (AAP), the initial recommended dose of chlorthalidone is 0.3 mg/kg, with a maximum daily dose of 2 mg/kg (or 50 mg per day). [22]"}
{"id": "article-57164_22", "title": "Chlorthalidone -- Administration -- Specific Patient Populations", "content": "Older patients: The patient's age is also a consideration when determining the appropriate chlorthalidone dosage. Lower initial doses, typically ranging from 6.25 mg to 12.5 mg daily, are recommended, with gradual titration as needed.\u00a0Diuretic medications, such as chlorthalidone, a Beers criteria medication, should be used cautiously. [23]", "contents": "Chlorthalidone -- Administration -- Specific Patient Populations. Older patients: The patient's age is also a consideration when determining the appropriate chlorthalidone dosage. Lower initial doses, typically ranging from 6.25 mg to 12.5 mg daily, are recommended, with gradual titration as needed.\u00a0Diuretic medications, such as chlorthalidone, a Beers criteria medication, should be used cautiously. [23]"}
{"id": "article-57164_23", "title": "Chlorthalidone -- Adverse Effects", "content": "Significant adverse effects are electrolyte derangement (hypokalemia, hyponatremia, etc), hypersensitivity reaction, and precipitation of acute gout attacks.", "contents": "Chlorthalidone -- Adverse Effects. Significant adverse effects are electrolyte derangement (hypokalemia, hyponatremia, etc), hypersensitivity reaction, and precipitation of acute gout attacks."}
{"id": "article-57164_24", "title": "Chlorthalidone -- Adverse Effects", "content": "The adverse effects of chlorthalidone\u00a0involve\u00a0most organ systems to differing degrees and manifestations. Of significance, electrolyte derangement is a commonly reported adverse effect of this medication, which results from\u00a0increased diuresis and altering of nephron physiology. Most commonly, chlorthalidone causes hypokalemia, but it may also cause hyponatremia or hypochloremia.\u00a0These known derangements\u00a0make monitoring serum electrolytes essential for patients receiving\u00a0chlorthalidone periodically throughout hypertensive management. Reported\u00a0adverse effects (per the Food and Drug Administration): Gastrointestinal\u00a0adverse effects: anorexia, gastritis, nausea, emesis, cramping, loose stools, constipation, and pancreatitis [24] Neurologic\u00a0reactions: paresthesias, dizziness, and headaches Hematologic reactions: aplastic anemia, leukopenia, agranulocytosis, and thrombocytopenia Cardiovascular reaction: orthostatic hypotension", "contents": "Chlorthalidone -- Adverse Effects. The adverse effects of chlorthalidone\u00a0involve\u00a0most organ systems to differing degrees and manifestations. Of significance, electrolyte derangement is a commonly reported adverse effect of this medication, which results from\u00a0increased diuresis and altering of nephron physiology. Most commonly, chlorthalidone causes hypokalemia, but it may also cause hyponatremia or hypochloremia.\u00a0These known derangements\u00a0make monitoring serum electrolytes essential for patients receiving\u00a0chlorthalidone periodically throughout hypertensive management. Reported\u00a0adverse effects (per the Food and Drug Administration): Gastrointestinal\u00a0adverse effects: anorexia, gastritis, nausea, emesis, cramping, loose stools, constipation, and pancreatitis [24] Neurologic\u00a0reactions: paresthesias, dizziness, and headaches Hematologic reactions: aplastic anemia, leukopenia, agranulocytosis, and thrombocytopenia Cardiovascular reaction: orthostatic hypotension"}
{"id": "article-57164_25", "title": "Chlorthalidone -- Adverse Effects", "content": "Dermatologic\u00a0reactions: purpura, photosensitivity, rash, urticaria, necrotizing angiitis (cutaneous vasculitis), Lyell syndrome (toxic epidermal necrolysis), pseudoporphyria [25] Other adverse reactions\u00a0include hyperglycemia, glycosuria, muscle spasm, weakness, restlessness, impotence, and hyperuricemia. [26]", "contents": "Chlorthalidone -- Adverse Effects. Dermatologic\u00a0reactions: purpura, photosensitivity, rash, urticaria, necrotizing angiitis (cutaneous vasculitis), Lyell syndrome (toxic epidermal necrolysis), pseudoporphyria [25] Other adverse reactions\u00a0include hyperglycemia, glycosuria, muscle spasm, weakness, restlessness, impotence, and hyperuricemia. [26]"}
{"id": "article-57164_26", "title": "Chlorthalidone -- Adverse Effects -- Drug-Drug Interactions", "content": "Digitalis: Medications like digitalis can influence serum electrolyte levels, potentially leading to warning signs such as dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscle fatigue, low blood pressure, decreased urine output, rapid heart rate, and gastrointestinal issues like nausea and vomiting. Insulin and oral hypoglycemic agents: Chlorthalidone therapy may affect insulin needs in\u00a0patients with diabetes, potentially necessitating adjustments in insulin dosage or requirements for higher doses of oral hypoglycemic agents. Additionally, latent diabetes may become apparent during treatment with chlorthalidone. Tubocurarine: Chlorthalidone and similar drugs can increase sensitivity to tubocurarine, affecting its action. Norepinephrine: Chlorthalidone may diminish arteries' responsiveness to norepinephrine, although the effect is not significant enough to render norepinephrine ineffective for therapeutic use.", "contents": "Chlorthalidone -- Adverse Effects -- Drug-Drug Interactions. Digitalis: Medications like digitalis can influence serum electrolyte levels, potentially leading to warning signs such as dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscle fatigue, low blood pressure, decreased urine output, rapid heart rate, and gastrointestinal issues like nausea and vomiting. Insulin and oral hypoglycemic agents: Chlorthalidone therapy may affect insulin needs in\u00a0patients with diabetes, potentially necessitating adjustments in insulin dosage or requirements for higher doses of oral hypoglycemic agents. Additionally, latent diabetes may become apparent during treatment with chlorthalidone. Tubocurarine: Chlorthalidone and similar drugs can increase sensitivity to tubocurarine, affecting its action. Norepinephrine: Chlorthalidone may diminish arteries' responsiveness to norepinephrine, although the effect is not significant enough to render norepinephrine ineffective for therapeutic use."}
{"id": "article-57164_27", "title": "Chlorthalidone -- Adverse Effects", "content": "Lithium: Close monitoring of lithium levels is imperative in individuals undergoing lithium treatment due to the potential of diuretics such as chlorthalidone to diminish lithium excretion, consequently triggering lithium toxicity. [27]", "contents": "Chlorthalidone -- Adverse Effects. Lithium: Close monitoring of lithium levels is imperative in individuals undergoing lithium treatment due to the potential of diuretics such as chlorthalidone to diminish lithium excretion, consequently triggering lithium toxicity. [27]"}
{"id": "article-57164_28", "title": "Chlorthalidone -- Contraindications -- Absolute Contraindications", "content": "Hypersensitivity to chlorthalidone Hypersensitivity to the sulfonamides-derived\u00a0medications Anuria", "contents": "Chlorthalidone -- Contraindications -- Absolute Contraindications. Hypersensitivity to chlorthalidone Hypersensitivity to the sulfonamides-derived\u00a0medications Anuria"}
{"id": "article-57164_29", "title": "Chlorthalidone -- Contraindications -- Warning and Precautions", "content": "Advanced chronic kidney disease Significant electrolyte derangement (severe hypokalemia, severe hyponatremia) Orthostatic hypotension Syncope Older adult\u00a0population (due to risk of hyponatremia) Pregnancy Hypercalcemia Severe hyperuricemia or gout [26]", "contents": "Chlorthalidone -- Contraindications -- Warning and Precautions. Advanced chronic kidney disease Significant electrolyte derangement (severe hypokalemia, severe hyponatremia) Orthostatic hypotension Syncope Older adult\u00a0population (due to risk of hyponatremia) Pregnancy Hypercalcemia Severe hyperuricemia or gout [26]"}
{"id": "article-57164_30", "title": "Chlorthalidone -- Contraindications", "content": "A recent study investigated the effects of potassium magnesium citrate (KMgCit) versus potassium chloride (KCl) supplementation during chlorthalidone therapy for hypertension. The primary goal of this study was to evaluate changes in metabolic parameters. The study found that chlorthalidone alone increased fasting plasma glucose levels and reduced serum potassium, magnesium, and urinary citrate excretion. However, supplementation with KMgCit attenuated the rise in fasting plasma glucose compared to KCl. These findings suggest that KMgCit may be more effective than KCl in preventing chlorthalidone-induced hyperglycemia, potentially enhancing tolerability and cardiovascular safety. [28]", "contents": "Chlorthalidone -- Contraindications. A recent study investigated the effects of potassium magnesium citrate (KMgCit) versus potassium chloride (KCl) supplementation during chlorthalidone therapy for hypertension. The primary goal of this study was to evaluate changes in metabolic parameters. The study found that chlorthalidone alone increased fasting plasma glucose levels and reduced serum potassium, magnesium, and urinary citrate excretion. However, supplementation with KMgCit attenuated the rise in fasting plasma glucose compared to KCl. These findings suggest that KMgCit may be more effective than KCl in preventing chlorthalidone-induced hyperglycemia, potentially enhancing tolerability and cardiovascular safety. [28]"}
{"id": "article-57164_31", "title": "Chlorthalidone -- Monitoring", "content": "The following items require periodic monitoring when the patients take chlorthalidone. Serum electrolytes : Serum sodium, potassium, chloride, and calcium levels should be monitored. [29] Fluid status and blood pressure : All patients taking chlorthalidone require observation for dryness of mouth, thirst, lethargy, hypotension, oliguria, tachycardia, palpitations, and gastrointestinal disturbances, such as nausea and vomiting. Chlorthalidone is a diuretic, so an inappropriately high dose can cause severe volume depletion. Magnesium level : It can increase the urinary excretion of magnesium and may result in hypomagnesemia. Uric acid level : Hyperuricemia may occur, or frank gout may be precipitated in certain patients receiving chlorthalidone. Serum glucose level: Serum glucose may increase with chronic use. There is insufficient research on teratogenicity, but\u00a0chlorthalidone\u00a0should be used during pregnancy only if\u00a0absolutely necessary.", "contents": "Chlorthalidone -- Monitoring. The following items require periodic monitoring when the patients take chlorthalidone. Serum electrolytes : Serum sodium, potassium, chloride, and calcium levels should be monitored. [29] Fluid status and blood pressure : All patients taking chlorthalidone require observation for dryness of mouth, thirst, lethargy, hypotension, oliguria, tachycardia, palpitations, and gastrointestinal disturbances, such as nausea and vomiting. Chlorthalidone is a diuretic, so an inappropriately high dose can cause severe volume depletion. Magnesium level : It can increase the urinary excretion of magnesium and may result in hypomagnesemia. Uric acid level : Hyperuricemia may occur, or frank gout may be precipitated in certain patients receiving chlorthalidone. Serum glucose level: Serum glucose may increase with chronic use. There is insufficient research on teratogenicity, but\u00a0chlorthalidone\u00a0should be used during pregnancy only if\u00a0absolutely necessary."}
{"id": "article-57164_32", "title": "Chlorthalidone -- Toxicity -- Signs and Symptoms of Overdose", "content": "Nausea Weakness Dizziness due to severe hypotension Electrolyte disturbances such as hypokalemia, hyponatremia, and hypomagnesemia", "contents": "Chlorthalidone -- Toxicity -- Signs and Symptoms of Overdose. Nausea Weakness Dizziness due to severe hypotension Electrolyte disturbances such as hypokalemia, hyponatremia, and hypomagnesemia"}
{"id": "article-57164_33", "title": "Chlorthalidone -- Toxicity -- Management\u00a0of acute overdosage", "content": "No specific antidote is available Gastric lavage Supportive management includes intravenous dextrose or normal saline for hypotension and intravenous potassium chloride for severe hypokalemia.", "contents": "Chlorthalidone -- Toxicity -- Management\u00a0of acute overdosage. No specific antidote is available Gastric lavage Supportive management includes intravenous dextrose or normal saline for hypotension and intravenous potassium chloride for severe hypokalemia."}
{"id": "article-57164_34", "title": "Chlorthalidone -- Enhancing Healthcare Team Outcomes", "content": "As a sulfonamide-derived medication, the clinician must review relevant allergies when prescribing chlorthalidone. An interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialists, nurse practitioners, physician assistants, nurses, and pharmacists, can help to maintain updated allergies. A review of allergies can start upon reception by asking patients to review their previous chart and update relevant sections, including allergies. While in a hospital setting, it can be prompted before administration by the nurse. In a pharmacy setting, the pharmacist can inquire before dispensing chlorthalidone. Additionally, EMR software now allows an additional barrier with risk-advisory when prescribing medication to which patients are allergic. [30]", "contents": "Chlorthalidone -- Enhancing Healthcare Team Outcomes. As a sulfonamide-derived medication, the clinician must review relevant allergies when prescribing chlorthalidone. An interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialists, nurse practitioners, physician assistants, nurses, and pharmacists, can help to maintain updated allergies. A review of allergies can start upon reception by asking patients to review their previous chart and update relevant sections, including allergies. While in a hospital setting, it can be prompted before administration by the nurse. In a pharmacy setting, the pharmacist can inquire before dispensing chlorthalidone. Additionally, EMR software now allows an additional barrier with risk-advisory when prescribing medication to which patients are allergic. [30]"}
{"id": "article-57164_35", "title": "Chlorthalidone -- Enhancing Healthcare Team Outcomes", "content": "In addition to allergies, clinicians, nurses, and pharmacists are responsible for counseling the patient, verifying dosing, and monitoring for adverse events. Pharmacists must also perform medication reconciliation to preclude any possible drug-drug interactions and notify the other interprofessional healthcare team members when concerns arise.", "contents": "Chlorthalidone -- Enhancing Healthcare Team Outcomes. In addition to allergies, clinicians, nurses, and pharmacists are responsible for counseling the patient, verifying dosing, and monitoring for adverse events. Pharmacists must also perform medication reconciliation to preclude any possible drug-drug interactions and notify the other interprofessional healthcare team members when concerns arise."}
{"id": "article-57164_36", "title": "Chlorthalidone -- Enhancing Healthcare Team Outcomes", "content": "Updating the type of adverse reaction occurring with the allergy is vital to avoid and characterize the true allergy. Deciphering whether a true allergy or previous adverse effects\u00a0from a medication is crucial as it changes therapeutic options for the patient. [30] The interprofessional paradigm will contribute to positive patient outcomes when using chlorthalidone.", "contents": "Chlorthalidone -- Enhancing Healthcare Team Outcomes. Updating the type of adverse reaction occurring with the allergy is vital to avoid and characterize the true allergy. Deciphering whether a true allergy or previous adverse effects\u00a0from a medication is crucial as it changes therapeutic options for the patient. [30] The interprofessional paradigm will contribute to positive patient outcomes when using chlorthalidone."}
{"id": "article-57164_37", "title": "Chlorthalidone -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Chlorthalidone -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}